After selling my company, I was invited to be the first healthcare and biotech partner at Y Combinator, where I could share my story and help other founders.

I'm Talia Frenkel, founder of L L, which creates safe and natural personal care products that give back. We raised our seed round of just over two and a half million dollars shortly after being part of Y Combinator in the summer of 2015.

At Candid, we have a much narrower focus compared to Palantir, concentrating on improving medical insurance billing for healthcare providers in the US, which is a massive industry.

Y Combinator has not seen significant financial success in healthcare, bio, industrials, or real estate, focusing instead on B2B and fintech for future growth.

I'm Elizabeth Iorns, the founder and CEO of Science Exchange, and I have a background in cancer biology, having completed my PhD at the Institute of Cancer Research in London and a postdoc at the University of Miami before starting Science Exchange in 2011 as part of Y Combinator's summer batch.

After exiting Y Combinator, we achieved $200,000 in revenue within six weeks, and by the end of the year, we reached about $1 million, showcasing our rapid growth trajectory.

My first company was called Accolade, which focused on online SAT prep, but we were rejected by Y Combinator because my co-founder and I were part-time and had other commitments.

After experiencing a health scare in high school, I realized how antiquated women's health care was, which inspired me to start a company focused on women's health.

I'm Liz Wessel, co-founder and CEO of WayUp, the largest marketplace for college students to find jobs and internships. We were part of Y Combinator in winter 2015 and have raised just over nine million dollars.